Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grey Wolf HealthTSXV:WOLF -9.60%52 PS Ratio is 1.54 as of Jul. 14, 2026, which is 41% above its 10-year median of 1.09. GuruFocus rates TSXV:WOLF with a GF Score™ of 52/100 and a GF Value™ of C$1.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Grey Wolf Health ranks better than 60.63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Grey Wolf Health's share price is C$1.60.
Grey Wolf Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was C$1.04. Hence, Grey Wolf Health's PS Ratio for today is 1.54.
Warning Sign:
Grey Wolf Health Corp stock PS Ratio (=1.68) is close to 5-year high of 1.72.
The historical rank and industry rank for Grey Wolf Health's PS Ratio or its related term are showing as below:
TSXV:WOLF'
s PS Ratio Range Over the Past 10 Years
Min: 0.72 Med: 1.09 Max: 1.72
Current: 1.54
During the past 5 years, Grey Wolf Health's highest PS Ratio was 1.72. The lowest was 0.72. And the median was 1.09.
TSXV:WOLF's PS Ratio is ranked better than 60.63% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs TSXV:WOLF: 1.54
During the past 5 years, Grey Wolf Health's highest 3-Year average Revenue per Share Growth Rate was 25.50% per year. The lowest was -9.50% per year. And the median was 8.00% per year.
Back to Basics: PS Ratio
Grey Wolf Health (TSXV:WOLF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Grey Wolf Health PS Ratio Related Terms
Grey Wolf Health PS Ratio Historical Data
* Premium members only.
The historical data trend for Grey Wolf Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Grey Wolf Health's Share Price of today is C$1.60. Grey Wolf Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Grey Wolf Health (TSXV:WOLF) has a PS Ratio of 1.54 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Grey Wolf Health and its competitors. This is 41% above median its historical median of 1.09. Over the past decade, Grey Wolf Health's PS Ratio has ranged from 0.72 to 1.72. According to the industry distribution chart, Grey Wolf Health ranks #376 out of 955 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is Grey Wolf Health's PS Ratio too high?
Grey Wolf Health's current PS Ratio of 1.54 is 41% above median its 10-year median of 1.09. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 1.72. The Drug Manufacturers industry median PS Ratio is 2.33. Grey Wolf Health's value of 1.54 is 33.9% below this industry median. Based on the distribution chart, Grey Wolf Health ranks #376 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grey Wolf Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's PS Ratio compare to ROL and SCI?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #376 out of 955 companies for PS Ratio. This puts Grey Wolf Health in the upper half of its industry. The industry median PS Ratio is 2.33. Grey Wolf Health's value of 1.54 is 33.9% below this benchmark. Historically, Grey Wolf Health's own PS Ratio has ranged from 0.72 to 1.72 over the past decade. While the company's 10-year median is 1.09 vs. the industry median of 2.33, Grey Wolf Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current PS Ratio of 1.54 is 33.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Grey Wolf Health and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current PS Ratio is 1.54, which is 41% above median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.10, compared to a current price of C$1.60 — trading 45.5% above its estimated fair value. The current PS Ratio is 1.54, which is 41% above median its 10-year median of 1.09 and 33.9% below the Drug Manufacturers industry median of 2.33. Grey Wolf Health's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current PS Ratio is 1.54 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.60 is trading 45.5% above its estimated GF Value™ of C$1.10.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
PS Ratio: 1.54 (41% above median its 10-year median of 1.09)
GF Value™: C$1.10 vs. price of C$1.60 (45.5% above fair value)
Industry Position: 33.9% below the Drug Manufacturers median (#376 of 955)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
52GF Score
Get the complete analysis for TSXV:WOLF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
